#Diabetes #Generics #Pharmaceuticals
ca.finance.yahoo.com
Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India
HYDERABAD, March 19 (Reuters) - India's market for diabetes and weight-loss drugs is set for a shake-up as Danish drugmaker Novo Nordisk's patent on semaglutide expires this week, triggering a wave of cheaper generics from local drugmakers and worries about uneven oversight in an overcrowded market.
B
#MentalHealth #DiabetesTreatment #ObesityManagement
www.bloomberg.com
Study Shows Ozempic Is Linked to Lower Risk of Worsening Mental Health Issues
Swedish people with depression and anxiety who took Novo Nordisk A/S's blockbuster shots Ozempic and Wegovy were less likely to see their mental health get worse, the latest data to suggest that popular diabetes and obesity drugs could also have a broader impact on well-being.
#Diabetes #Hypertension #CardiovascularHealth
www.medscape.com
Early Hypertension Linked to a Poorer Prognosis in T2D
In patients with type 2 diabetes (T2D), both young-onset hypertension (onset before the age of 45 years) and late-onset hypertension (onset at the age of 45 years or later) were associated with higher risks for cardiovascular disease (CVD), congestive heart failure, chronic kidney disease, and all-cause mortality, with young-onset hypertension linked to poorer outcomes.
S
#Diabetes #Insulin #HealthCare
scitechdaily.com
One of the Most Common Diabetes Treatments May Be Making the Disease Worse, Study Warns
A new study suggests that one of the most common diabetes treatments may speed type 2 diabetes progression by causing insulin-producing cells to lose their functional identity.
